The pill form of Ozempic is called Rybelsus. Both medications contain the same active ingredient, semaglutide, and are made by the same manufacturer, Novo Nordisk. The key difference is how you take them: Ozempic is a once-weekly injection, while Rybelsus is a tablet you swallow once a day. Rybelsus is currently approved for type 2 diabetes, not for weight loss.
How Rybelsus Works as a Pill
Semaglutide is a protein-based drug, which means stomach acid would normally destroy it before it could do anything useful. To solve this, each Rybelsus tablet contains an absorption enhancer that does two things at once: it temporarily neutralizes the acid right around the tablet and briefly increases the permeability of the stomach lining so semaglutide can pass through into the bloodstream. This all happens in a tiny, localized area where the tablet sits, which is why following the dosing instructions precisely matters so much.
How to Take It
Rybelsus has stricter dosing rules than most pills. You take it first thing in the morning on a completely empty stomach, with no more than 4 ounces of plain water. Then you wait at least 30 minutes before eating, drinking anything else, or taking other medications. Eating or drinking sooner reduces how much of the drug your body absorbs. Waiting longer than 30 minutes can actually increase absorption slightly.
This daily routine is one of the biggest practical differences from Ozempic, which only requires a single injection per week with no food-timing restrictions.
Available Doses and Titration
Rybelsus comes in three strengths: 3 mg, 7 mg, and 14 mg. All are white to light yellow, oval-shaped tablets. You start at 3 mg once daily for 30 days, but that starter dose isn’t strong enough to control blood sugar on its own. It exists purely to let your body adjust. After 30 days, you move up to 7 mg daily. If you need more blood sugar control after another 30 days at 7 mg, your dose can increase to 14 mg.
How Rybelsus Compares to Ozempic
Because no head-to-head clinical trials have directly compared the two, the best evidence comes from observational data. One study of real-world patients found that both groups lost similar amounts of weight, roughly 13 pounds after six months. In separate clinical trials, Rybelsus patients lost up to about 8 pounds over 26 weeks, while Ozempic patients lost up to about 10 pounds over 30 weeks. The numbers are close enough that the choice between them often comes down to whether you prefer a daily pill or a weekly injection.
One important distinction: Ozempic is approved for type 2 diabetes, and its higher-dose sibling Wegovy is approved for weight management. Rybelsus currently carries only the type 2 diabetes approval, though doctors can prescribe it off-label.
Common Side Effects
The side effect profile mirrors what you’d expect from any semaglutide product. Nausea is the most common complaint, affecting 11% of people on the 7 mg dose and 20% on the 14 mg dose in clinical trials, compared to 6% on placebo. Stomach pain, diarrhea, reduced appetite, vomiting, and constipation round out the list. Overall, about 32% of people on the 7 mg dose and 41% on the 14 mg dose experienced some kind of gastrointestinal issue.
Most of these symptoms show up during the dose increases and tend to ease with time. Still, about 4% of people on 7 mg and 8% on 14 mg dropped out of trials specifically because of gut-related side effects, compared to just 1% on placebo. Less common issues include bloating, heartburn, acid reflux, and gas.
Cost
Rybelsus has a list price of $997.58 per month, regardless of which dose you take. That’s roughly comparable to Ozempic’s list price. If you have commercial insurance through an employer or purchased on your own, Novo Nordisk offers a savings card that may reduce your out-of-pocket cost. Actual copays vary widely depending on your insurance plan and pharmacy.
Higher-Dose Tablets in Development
Novo Nordisk has been testing a 50 mg oral semaglutide tablet specifically for weight loss, a significant jump from the current 14 mg maximum. In a phase 3 trial of 667 adults with overweight or obesity, the 50 mg dose produced an average weight loss of 15.1% over 68 weeks, compared to 2.4% with placebo. More than half of participants lost at least 15% of their body weight, and about a third lost 20% or more. Gastrointestinal side effects were common, with 80% of people in the treatment group reporting some stomach-related issue, though most were mild to moderate. If approved, this higher-dose tablet could offer an oral alternative to injectable weight loss medications like Wegovy.